{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:17:53Z","timestamp":1778606273215,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T00:00:00Z","timestamp":1090972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long\u2010acting risperidone, the first long\u2010acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and safety of long\u2010acting injectable risperidone in elderly patients with psychotic disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a subanalysis of 57 patients aged \u226565 years enrolled in an open\u2010label study of long\u2010acting risperidone that included 725 symptomatically stable patients with schizophrenia or schizoaffective disorder. Patients were assigned to receive 25, 50, or 75\u2009mg of long\u2010acting risperidone every 2 weeks for up to 50 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010seven elderly patients (mean\u2009\u00b1\u2009SE age, 70.9\u2009\u00b1\u20090.7 years) were enrolled. Mean Positive and Negative Syndrome Scale (PANSS) total scores improved significantly throughout the study and at endpoint (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility\/excitement, and anxiety\/depression) also significantly improved (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Clinical improvement (\u226520% reduction in PANSS total scores) was achieved by 49% of these stable patients, and 55% improved on the Clinical Global Impressions scale. Severity of movement disorders (Extrapyramidal Symptom Rating Scale scores) was reduced significantly. Adverse events reported in &gt;10% of patients were insomnia (14%), constipation (12%), and bronchitis (12%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long\u2010acting risperidone was associated with significant symptom improvements in stable elderly patients with schizophrenia or schizoaffective disorder. Treatment was well tolerated. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.1184","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T10:08:16Z","timestamp":1091009296000},"page":"898-905","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy and safety of long\u2010acting risperidone in elderly patients with schizophrenia and schizoaffective disorder"],"prefix":"10.1002","volume":"19","author":[{"given":"Robert A.","family":"Lasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Gharabawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00eblle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,7,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.1.23"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1104"},{"key":"e_1_2_1_4_1","unstructured":"ChouinardG LasserR BossieC ZhuY GharabawiG.2003.Lower risk of tardive dyskinesia in patients with schizophrenia treated with a long\u2010acting injectable atypical antipsychotic.Poster Presented at the International Congress on Schizophrenia Research 29 March\u20132 April 2003 Colorado Springs Colorado."},{"key":"e_1_2_1_5_1","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard G","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.49.2.196"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.2.197"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1166(200006)15:6<506::AID-GPS146>3.0.CO;2-V"},{"key":"e_1_2_1_9_1","first-page":"24","article-title":"Dose response of prophylactic antipsychotics","volume":"54","author":"Davis JM","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447050-00004"},{"key":"e_1_2_1_11_1","unstructured":"EerdekensM RasmussenM VermeulenA LowenthalR Van PeerA.2000.Kinetics and safety of a novel risperidone depot. Presented at American Psychiatric Association 2000 Annual Meeting 13\u201318 May 2000; Chicago IL.New Research Abstracts NR669."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00142-0"},{"key":"e_1_2_1_13_1","first-page":"51053","volume-title":"Guidance for Industry on Content and Format of Geriatric Labeling","author":"Federal Register Notice","year":"2001"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1017"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-14282"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0617"},{"key":"e_1_2_1_17_1","first-page":"426","article-title":"Depot neuroleptic therapy: an underutilized treatment option","volume":"53","author":"Glazer WM","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_18_1","unstructured":"GuyE(ed.).1976. Clinical global impressions. InECDEU Assessment Manual for Psychopharmacology revised. DHEW Pub. No. (ADM) 76. National Institutes of Mental Health Department of Health Education and Welfare: Rockville MD; 218\u2013220."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7002.421"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb01595.x"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200311000-00008"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950210050010"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/09540269009026605"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb00351.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00045-X"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1007"},{"key":"e_1_2_1_29_1","unstructured":"LasserR RodriguezS BossieC GharabawiG KaneJM.2003.Core symptom remission in patients with schizophrenia receiving long\u2010acting risperidone. American Psychiatric Association 2003 Annual meeting San Francisco CA 17\u201322 May 2003.New Research Abstracts NR528."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199905000-00006"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"issue":"8","key":"e_1_2_1_32_1","first-page":"43","article-title":"Side effects of antipsychotics in the elderly","volume":"61","author":"Masand PS","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.6.805"},{"issue":"13","key":"e_1_2_1_34_1","first-page":"21","article-title":"Use of quetiapine in elderly patients","volume":"63","author":"Tariot PN","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_35_1","volume-title":"SF\u201036 Physical and Mental Health Summary Scales: A User's Manual","author":"Ware J","year":"1994"},{"key":"e_1_2_1_36_1","first-page":"106","article-title":"Medication noncompliance in schizophrenia","volume":"3","author":"Weiden P","year":"1997","journal-title":"J Pract Psychiatry Behav Health"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.419"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.2.325"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.1184","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.1184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:12:40Z","timestamp":1700197960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.1184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,28]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1002\/gps.1184"],"URL":"https:\/\/doi.org\/10.1002\/gps.1184","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,28]]}}}